Anaptysbio, Inc 8-K, filed Nov 12, 2026
Anaptysbio, Inc (ANAB)
About this 8-K
Anaptysbio, Inc filed this 8-K on November 12, 2026.
AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027. AI summary
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
Exhibit Title or Description |
99.1 |
|
104 |
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
AnaptysBio, Inc. |
|
|
|
|
Date: |
November 12, 2026 |
By: |
/s/ Christopher M. Murphy |
|
|
|
Name: Christopher M. Murphy |
Exhibit 99.1
Anaptys Reports Fiscal First Quarter 2027 Financial Results and
Provides Business Update
SAN DIEGO, November 12, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update.
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications,” said Daniel Faga, president and chief executive officer. “We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
GSK Jemperli Financial Collaboration
Vanda Quimilza (imsidolimab) Financial Collaboration
GSK and Tesaro Litigation Update
Fiscal First Quarter Financial Results
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to future clinical, commercial and regulatory developments for Jemperli and Quimilza, future royalty amounts, the Company’s expected paydown of its obligations to Sagard, and the timing or outcome of the Company’s ongoing litigation with GSK. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to commercial success of the Company’s licensed products, the company’s ability to protect its financial collaborations and return value to its shareholders, the company’s ability to operate efficiently with a limited staff, and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
About Anaptys
Anaptys manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Chris Murphy
Chief Financial Officer
investors@anaptysbio.com
_______________________________________
1. GSK Q3 2026 earnings call, 10/28/2026
2. CEO Emma Walmsley, 2025 JP Morgan CEO Series fireside chat, 9/11/2025, “there's no change to our peak year sales overall ambition for Jemperli, that's for sure, which is far more than £2 billion.”; Converted from GBP to USD using Q3 2025 average exchange rate (1.35x)
AnaptysBio, Inc.
Balance Sheets
(in thousands, except par value data)
(unaudited)
|
|
September 30, 2026 |
|
|
June 30, 2026 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
135,394 |
|
|
$ |
133,826 |
|
Receivables from collaborative partners |
|
|
30,494 |
|
|
|
25,634 |
|
Short-term investments |
|
|
17,599 |
|
|
|
30,317 |
|
Prepaid expenses and other current assets |
|
|
4,886 |
|
|
|
8,650 |
|
Total current assets |
|
|
188,373 |
|
|
|
198,427 |
|
Property and equipment, net |
|
|
97 |
|
|
|
102 |
|
Deferred tax asset |
|
|
107,247 |
|
|
|
106,639 |
|
Operating lease right-of-use assets |
|
|
11,070 |
|
|
|
11,560 |
|
Other long-term assets |
|
|
256 |
|
|
|
256 |
|
Total assets |
|
$ |
307,043 |
|
|
$ |
316,984 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
879 |
|
|
$ |
4,394 |
|
Accrued expenses |
|
|
19,339 |
|
|
|
28,798 |
|
Current portion of operating lease liability |
|
|
2,203 |
|
|
|
2,161 |
|
Total current liabilities |
|
|
22,421 |
|
|
|
35,353 |
|
Liability related to sale of future royalties |
|
|
249,819 |
|
|
|
256,493 |
|
Long-term taxes payable |
|
|
3,619 |
|
|
|
3,619 |
|
Operating lease liability, net of current portion |
|
|
10,364 |
|
|
|
10,934 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued or outstanding at September 30, 2026 and June 30, 2026, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 500,000 shares authorized, 29,941 shares and 29,728 shares issued and outstanding at September 30, 2026 and June 30, 2026, respectively |
|
|
30 |
|
|
|
30 |
|
Additional paid in capital |
|
|
658,658 |
|
|
|
652,269 |
|
Accumulated other comprehensive loss |
|
|
(181 |
) |
|
|
(151 |
) |
Accumulated deficit |
|
|
(637,687 |
) |
|
|
(641,563 |
) |
Total stockholders’ equity |
|
|
20,820 |
|
|
|
10,585 |
|
Total liabilities and stockholders’ equity |
|
$ |
307,043 |
|
|
$ |
316,984 |
|
AnaptysBio, Inc.
Statements of Operations and Comprehensive Income
(in thousands, except per share data)
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Collaboration revenue |
|
$ |
30,274 |
|
|
$ |
76,320 |
|
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
(1,267 |
) |
|
|
(2,035 |
) |
General and administrative |
|
|
11,636 |
|
|
|
1,083 |
|
Total operating expenses |
|
|
10,369 |
|
|
|
(952 |
) |
Income from operations |
|
|
19,905 |
|
|
|
77,272 |
|
Other income (expense), net: |
|
|
|
|
|
|
||
Interest income |
|
|
1,438 |
|
|
|
1,861 |
|
Sublease income |
|
|
667 |
|
|
|
— |
|
Non-cash interest expense for the sale of future royalties |
|
|
(18,742 |
) |
|
|
(22,515 |
) |
Total other expense, net |
|
|
(16,637 |
) |
|
|
(20,654 |
) |
Income before income taxes |
|
|
3,268 |
|
|
|
56,618 |
|
Benefit (provision) for income taxes |
|
|
608 |
|
|
|
(269 |
) |
Income from continuing operations |
|
|
3,876 |
|
|
|
56,349 |
|
Loss from discontinued operations, net of tax |
|
|
— |
|
|
|
(41,236 |
) |
Net income |
|
|
3,876 |
|
|
|
15,113 |
|
Other comprehensive income: |
|
|
|
|
|
|
||
Unrealized (loss) gain on available for sale securities |
|
|
(30 |
) |
|
|
53 |
|
Total comprehensive income |
|
$ |
3,846 |
|
|
$ |
15,166 |
|
Net income (loss) per common share: |
|
|
|
|
|
|
||
Income from continuing operations - basic |
|
$ |
0.13 |
|
|
$ |
2.02 |
|
Loss from discontinued operations - basic |
|
|
— |
|
|
|
(1.48 |
) |
Net income per common share - basic |
|
$ |
0.13 |
|
|
$ |
0.54 |
|
Income from continuing operations - diluted |
|
$ |
0.11 |
|
|
$ |
1.94 |
|
Loss from discontinued operations - diluted |
|
|
— |
|
|
|
(1.42 |
) |
Net income per common share - diluted |
|
$ |
0.11 |
|
|
$ |
0.52 |
|
Weighted-average number of shares outstanding: |
|
|
|
|
|
|
||
Basic |
|
|
29,847 |
|
|
|
27,833 |
|
Diluted |
|
|
35,072 |
|
|
|
29,018 |
|